- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2644EUR$2,750USD£2,268GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- April 2021
China
From €2500EUR$2,600USD£2,145GBP
- Report
- January 2019
- 29 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- January 2019
- 82 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- January 2019
- 40 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- January 2019
- 18 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Drug Pipelines
- January 2019
- 510 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Drug Pipelines
- October 2018
- 475 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Report
- April 2018
- 196 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Drug Pipelines
- December 2022
- 36 Pages
Global
From €9611EUR$9,995USD£8,245GBP
- Report
- October 2021
- 57 Pages
Global
From €6726EUR$6,995USD£5,770GBP
- Report
- June 2019
- 147 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Report
- July 2020
- 1740 Pages
Global
From €4615EUR$4,800USD£3,959GBP
- Clinical Trials
- November 2018
- 1100 Pages
Global
From €2885EUR$3,000USD£2,475GBP
- Report
- April 2018
United States
From €7688EUR$7,995USD£6,595GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Report
- November 2023
- 103 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Drug Pipelines
- March 2021
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- February 2023
- 392 Pages
Global
From €5510EUR$5,730USD£4,727GBP
Rituxan (rituximab) is a monoclonal antibody used to treat a variety of immune disorders, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis. It is used in combination with other drugs to treat these conditions. Rituxan works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response.
Rituxan is a biologic drug, meaning it is made from living cells. It is administered intravenously and is typically given in two doses, two weeks apart. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain immune disorders.
Rituxan is a widely used drug in the immune disorders market. It is one of the most prescribed drugs for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. It is also used off-label to treat other conditions, such as systemic lupus erythematosus.
Some companies in the Rituxan market include Genentech, Biogen, and Roche. Show Less Read more